RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Taro Pharmaceutical Industries Stock

Taro Pharmaceutical Industries EBIT 2025

Taro Pharmaceutical Industries EBIT

98.2 M USD

Ticker

TARO

ISIN

IL0010827181

WKN

897505

In 2025, Taro Pharmaceutical Industries's EBIT was 98.2 M USD, a 356.57% increase from the 21.51 M USD EBIT recorded in the previous year.

The Taro Pharmaceutical Industries EBIT history

YEAREBIT (undefined USD)
2025e98.2
202421.51
202317.7
2022125
2021145.1
2020246.5
2019292.5
2018304.9
2017515.3
2016617.5
2015523.4
2014432.9
2013361.9
201266.2
2011204.7
201089.2
200975.3
200857
200767.9
2006-16.6
20059.5

Taro Pharmaceutical Industries Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Taro Pharmaceutical Industries, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Taro Pharmaceutical Industries from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Taro Pharmaceutical Industries’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Taro Pharmaceutical Industries. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Taro Pharmaceutical Industries’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Taro Pharmaceutical Industries’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Taro Pharmaceutical Industries’s growth potential.

Taro Pharmaceutical Industries Revenue, EBIT and net profit per share

DateTaro Pharmaceutical Industries RevenueTaro Pharmaceutical Industries EBITTaro Pharmaceutical Industries Net Income
2025e690 M undefined98.2 M undefined107.01 M undefined
2024629.18 M undefined21.51 M undefined53.87 M undefined
2023573 M undefined17.7 M undefined25.4 M undefined
2022561.3 M undefined125 M undefined58.3 M undefined
2021549 M undefined145.1 M undefined-386.7 M undefined
2020644.8 M undefined246.5 M undefined244.2 M undefined
2019669.9 M undefined292.5 M undefined281.8 M undefined
2018661.9 M undefined304.9 M undefined211.2 M undefined
2017879.4 M undefined515.3 M undefined456.4 M undefined
2016950.8 M undefined617.5 M undefined540.9 M undefined
2015862.9 M undefined523.4 M undefined484.3 M undefined
2014759.3 M undefined432.9 M undefined360.4 M undefined
2013671 M undefined361.9 M undefined266.2 M undefined
2012145.1 M undefined66.2 M undefined47.3 M undefined
2011505.7 M undefined204.7 M undefined182.7 M undefined
2010392.5 M undefined89.2 M undefined64.1 M undefined
2009355.9 M undefined75.3 M undefined114 M undefined
2008327.4 M undefined57 M undefined30.5 M undefined
2007318.5 M undefined67.9 M undefined34.3 M undefined
2006252.3 M undefined-16.6 M undefined-82.7 M undefined
2005288.6 M undefined9.5 M undefined100,000 undefined

Taro Pharmaceutical Industries stock margins

The Taro Pharmaceutical Industries margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Taro Pharmaceutical Industries. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Taro Pharmaceutical Industries.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Taro Pharmaceutical Industries's sales revenue. A higher gross margin percentage indicates that the Taro Pharmaceutical Industries retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Taro Pharmaceutical Industries's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Taro Pharmaceutical Industries's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Taro Pharmaceutical Industries's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Taro Pharmaceutical Industries. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Taro Pharmaceutical Industries's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Taro Pharmaceutical Industries Margin History

Taro Pharmaceutical Industries Gross marginTaro Pharmaceutical Industries Profit marginTaro Pharmaceutical Industries EBIT marginTaro Pharmaceutical Industries Profit margin
2025e48.47 %14.23 %15.51 %
202448.47 %3.42 %8.56 %
202346.82 %3.09 %4.43 %
202252.22 %22.27 %10.39 %
202154.04 %26.43 %-70.44 %
202061.99 %38.23 %37.87 %
201966.53 %43.66 %42.07 %
201870.03 %46.06 %31.91 %
201776.36 %58.6 %51.9 %
201682.14 %64.95 %56.89 %
201578.41 %60.66 %56.12 %
201476.39 %57.01 %47.46 %
201373.74 %53.93 %39.67 %
201268.37 %45.62 %32.6 %
201165.16 %40.48 %36.13 %
201059.49 %22.73 %16.33 %
200958.72 %21.16 %32.03 %
200857.39 %17.41 %9.32 %
200759.78 %21.32 %10.77 %
200651.05 %-6.58 %-32.78 %
200557.52 %3.29 %0.03 %

Taro Pharmaceutical Industries Aktienanalyse

What does Taro Pharmaceutical Industries do?

Taro Pharmaceutical Industries Ltd. is a company that focuses on generic and specialized pharmaceutical products. The company was founded in Israel in 1950 and has since relocated its headquarters to Ireland. Taro Pharmaceutical has become one of the largest providers of generics and specialty drugs over the years due to its extensive experience, high-quality products, and ability to adapt to changing market conditions. The business model of Taro Pharmaceutical Industries is extremely simple. They offer affordable generic medications. The company's focus is on developing, manufacturing, and distributing generic products on the global market. Taro also has a wide range of specialty drugs, including dermatological and ophthalmology products. Taro Pharmaceutical Industries Ltd.'s business activities are divided into two divisions: Farmaceutica Taro, which specializes in the development, manufacturing, and distribution of generics and specialty drugs, and Taro Research & Development Center, which focuses on researching and developing new medications and generic products. Taro Pharmaceutical Industries Ltd. offers a wide range of products, including tablets, ointments, and eye drops. The company provides a variety of products in various therapeutic areas such as dermatology, cardiology, urology, gynecology, neurology, pediatrics, gastroenterology, and infectious diseases. The dermatological products of Taro Pharmaceutical, such as Clobetasol Propionate Cream and Lidocaine, are known for their effectiveness in skincare. With its eye products like Dorzolamide and Timolol Maleate Ophthalmic Solution, the company focuses on the ophthalmology field. Taro also produces medications that help with cardiovascular diseases, such as Amlodipine and Enalapril. Taro Pharmaceutical Industries Ltd. was founded in 1950 by chemist George Rosenberg and his partner Leo Ringer in Haifa, Israel. Manufacturing of pharmaceutical ingredients for drug production began in 1951. The company has been focused on growth since its inception and has built a strong reputation for its production quality. In 1969, Taro Pharmaceutical went public with a market capitalization of approximately 8 million US dollars. Over the years, the company expanded its portfolio and grew rapidly through acquisitions of other companies and expansion into international locations such as Canada, Switzerland, Mexico, Spain, and Italy. Taro Pharmaceutical was sold to Italian pharma company Ariston in 1993 and acquired by Indian pharma company Sun Pharmaceutical Industries in 2013. The company's headquarters is now in Dublin, Ireland, and it produces for markets worldwide, including North America, Europe, Asia, Australia, and South America. In conclusion, Taro Pharmaceutical Industries is one of the leading companies in the generic production field and has become a strong player in the specialized pharmaceutical products sector. The company has proven its expertise in research and development, manufacturing, and distribution of sought-after products. With the global demand for medications expected to continue rising, a company like Taro, which offers sustainable and affordable preventive solutions, plays an important role in the healthcare industry and will continue to do so in the future. Taro Pharmaceutical Industries ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Taro Pharmaceutical Industries's EBIT

Taro Pharmaceutical Industries's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Taro Pharmaceutical Industries's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Taro Pharmaceutical Industries's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Taro Pharmaceutical Industries’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Taro Pharmaceutical Industries stock

How much did Taro Pharmaceutical Industries achieve in EBIT for the current year?

In the current year, Taro Pharmaceutical Industries has achieved an EBIT of 98.2 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Taro Pharmaceutical Industries.

How has the EBIT of Taro Pharmaceutical Industries developed in recent years?

The EBIT of Taro Pharmaceutical Industries has increased by 356.571% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Taro Pharmaceutical Industries?

The EBIT of Taro Pharmaceutical Industries is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Taro Pharmaceutical Industries pay?

Over the past 12 months, Taro Pharmaceutical Industries paid a dividend of 12.86 USD . This corresponds to a dividend yield of about 29.93 %. For the coming 12 months, Taro Pharmaceutical Industries is expected to pay a dividend of 0 USD.

What is the dividend yield of Taro Pharmaceutical Industries?

The current dividend yield of Taro Pharmaceutical Industries is 29.93 %.

When does Taro Pharmaceutical Industries pay dividends?

Taro Pharmaceutical Industries pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries paid dividends every year for the past 1 years.

What is the dividend of Taro Pharmaceutical Industries?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Taro Pharmaceutical Industries located?

Taro Pharmaceutical Industries is assigned to the 'Health' sector.

Wann musste ich die Aktien von Taro Pharmaceutical Industries kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Taro Pharmaceutical Industries from 12/28/2018 amounting to 12.86 USD, you needed to have the stock in your portfolio before the ex-date on 12/10/2018.

When did Taro Pharmaceutical Industries pay the last dividend?

The last dividend was paid out on 12/28/2018.

What was the dividend of Taro Pharmaceutical Industries in the year 2024?

In the year 2024, Taro Pharmaceutical Industries distributed 0 USD as dividends.

In which currency does Taro Pharmaceutical Industries pay out the dividend?

The dividends of Taro Pharmaceutical Industries are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Taro Pharmaceutical Industries

Our stock analysis for Taro Pharmaceutical Industries Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Taro Pharmaceutical Industries Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.